ClinicalTrials.gg
RecruitingNCT06234332Updated Nov 24, 2025

Peking University Birth Cohort in Weifang (PKUBC-WF)

An observational study in Health Problems in Pregnancy, Pregnancy Outcomes and Gestational Diabetes, sponsored by Peking University. Recruiting at 1 site in China. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-11-24.

Sponsored by Peking University · Observational

How we know

From the registry’s dates

  • Started Feb 2024; still recruiting 2 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
2,800
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 68 studies in Diabetes, Gestational with a site in China — 19 open to participants now, 23 under way, none of them phase 3. Diabetes, Gestational · China.

Planned enrollment
12th of 29
2,800 · median 1,122
Started
2024
with 4 others
Observational
29 of 68
12 open now
Primary completion
2026-12
later than 15 of 22 live
Registered
55th of 68
by date
Lead sponsor
4 of 68
Peking University

Among the 68 studies in Diabetes, Gestational with a site in China, this one is the 12th largest by planned enrollment of the 29 observational ones that give a count, is one of 5 that started in 2024, is one of 29 observational ones, reaches primary completion later than 15 of the 22 other live ones, and was the 55th registered.

Diabetes, Gestational

878 studies on the registry are indexed under Diabetes, Gestational; 196 are open to participants now.

Browse Diabetes, Gestational studies →

Open to participants now

19 of the 68 studies in Diabetes, Gestational with a site in China are open now. Recruiting first, the newest first:

13 more — sign in →

All 19 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 132 Diabetes, Gestational studies recruiting now, 60 (45%) set no upper age limit and 70 (53%) stop at 75 or younger; 12 take children under 18; 60 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 68 studies in Diabetes, Gestational with a site in China, or all of them as a file.
02

Study summary

The PKUBC-WF is a prospective cohort study carried out in Weifang city of Shandong, China. The primary aim of this study is to investigate the short-term and long-term effects of pre-pregnant and prenatal exposure on maternal and child health. Data are collected regarding environmental, nutritional and lifestyle exposures as well as short-term and long-term health outcomes of mothers and their children from birth to before 18 years old. Biological samples including peripheral blood, urine, placenta, umbilical cord, cord blood, and faeces are also collected.

Read the detailed description

Maternal and child health is of great concern globally. Early life phase of a fetus and infant is a critical period for the development of health and disease in the whole life. Exposure of negative environmental, nutritional and lifestyle factors in pregnant women during this period can have adverse effects on fetal and infant. In addition, for mothers, complications during pregnancy could also have a negative effect on long-term health of mothers, such as diabetes, hypertension. Thus, the Peking University Birth Cohort in Weifang is primarily aimed to investigate the short-term and long-term effects of pre-pregnant and prenatal exposure on maternal and child health. Data are collected regarding environmental, nutritional and lifestyle exposures as well as short-term and long-term health outcomes of mothers, husbands and their children from birth to before 18 years old. Biological samples including peripheral blood, urine, placenta, umbilical cord, cord blood, and faeces samples are also collected.

03

Conditions studied

  • Health Problems in Pregnancy
  • Pregnancy Outcomes
  • Gestational Diabetes
  • Gestational Hypertension
  • Preterm Birth
  • Obesity
  • Mother-Infant Interaction
  • Child Development
  • Anemia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Pregnant women and their children in Weifang, China

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Pregnant woman

    1. Pregnant women, 6-13\^+6 gestational weeks
    2. Resided in Weifang in the past half years and have no plan to move out after delivery
    3. Pregnant women who plan to have antenatal care and delivery in Weifang maternal\&Child Hospital.
    4. Pregnant women who is willing to participate in this study with
  • Pregnant woman's husband

    1. His wife was eligible for enrollment
    2. He is the biological father of the child (his wife's current pregnancy)
    3. Pregnant women's husband who is willing to participate in this study with informed consent
  • Offspring 4. Children born to pregnant women who met the inclusion criteria after enrolling in this study.

    5. Before the age of 8 years, his/her mother provided written informed consent. 6. After 8 years old, he/she agreed to continue this study and signed the informed consent.

Exclusion criteria

Exclusion Criteria:

  • Participants who cannot communicate normally.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
2,800 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Exposure group

    Group with environmental, nutritional or lifestyle exposures

    Other: No Interventions

  • Non-exposed group

    Group without any environmental, nutritional and lifestyle exposures

Interventions

  • OtherNo Interventions

    No intervention This is an observational study without any intervention

06

What researchers measure

Primary outcomes

  1. Numbers and morbidity of participants with pregnancy complications

    Including gestational diabetes, gestational hypertension, anemia, and hypothyroidism during pregnancy

    Time frame: At delivery

  2. Numbers and morbidity of participants with adverse pregnancy outcomes

    Including preterm birth, low birth weight, macrosomia, abortion, stillbirth, and birth defects.

    Time frame: At delivery

Secondary outcomes

  1. Weight in kilogram changes during childhood

    Measured by health professionals in clinic

    Time frame: At birth and age at 6 weeks, 6 months, 12 months, 2 years, 3 years, 6 years, 9 years, 12 years, 15 years, and 17 years

  2. Height in centimeter changes during childhood

    Measured by health professionals in clinic

    Time frame: At birth and age at 6 weeks, 6 months, 12 months, 2 years, 3 years, 6 years, 9 years, 12 years, 15 years, and 17 years

  3. Early Child development

    Measured by Ages\&Stages Questionnaires (ASQ).There are 6 questions in each of 5 domains of development: communication, gross motor, fine motor, problem-solving skills, and adaptive skills. Each question is given a 10 (yes), 5 (sometimes), or 0 (not yet) score according to the parents' answers. The sum scores (range from 0 to 300) and scores for each domain (range from 0 to 60) are calculated. Chinese norms are available for each domain, and any domain screened \<2 SDs below the mean is considered a positive screening. A higher ASQ score means better development.

    Time frame: Age at 6 weeks, 6 months and 12 months

  4. Incidence of diabetes mellitus in women

    Measured by health professionals in clinic

    Time frame: 6 weeks after delivery and 3 years after delivery

  5. Incidence of hypertension in women

    Measured by health professionals in clinic

    Time frame: 6 weeks after delivery and 3 years after delivery

  6. Incidence of child overweight and obesity

    Measured by health professionals in clinic

    Time frame: At birth and age at 6 weeks, 6 months, 12 months, 2 years, 3 years, 6 years, 9 years, 12 years, 15 years, and 17 years

  7. Incidence of autism spectrum disorder in children

    Measured by The Modified Checklist for Autism in Toddlers, Revised with Follow-Up (M-CHAT-R/F) and Autism Behavior Checklist (ABC) scales

    Time frame: Age at 2 years, 3 years

  8. Incidence of attention-deficit/hyperactivity disorder in children

    Measured by The Child Behavior Checklist (CBC) scale

    Time frame: Age at 6 years

  9. Incidence of anxiety in adolescents

    Measured by Social Anxiety Scale for Adolescents (SAS-A) scale

    Time frame: Age at 9 years, 12 years, 15 years, and 17 years

  10. Incidence of depression in adolescents

    Measured by Beck Depression Inventory-II (BDI-II) scale

    Time frame: Age at 9 years, 12 years, 15 years, and 17 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2024 (actual). Primary completion is estimated for Dec 2026, 34 months after the start.

Of 142 non-industry observational studies under Diabetes, Gestational, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 70. This study's planned 34 months is below that.

Counting every sponsor, half of 144 studies reached it within 43 months; a quarter within 19 and three quarters within 73.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 23, 2024
First posted
Jan 31, 2024
StartActual
Feb 1, 2024
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2043
Last update
Nov 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06234332
Lead sponsor
Peking University
Collaborators
National Natural Science Foundation of China
Responsible party
Hai-Jun Wang (Prof., Peking University) — Principal investigator
First posted
Jan 31, 2024
Start date
Feb 1, 2024
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2043 (estimated)
Last update
Nov 24, 2025

Study contacts

Haijun Wang, Ph.D
Contact
whjun1@bjmu.edu.cn
86-010-82805583
Jue Liu, Ph.D
Contact
jueliu@bjmu.edu.cn
86-13426455743
Haijun Wang, Ph.D
principal investigator · Peking University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion